LT2744515T - Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis - Google Patents

Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis

Info

Publication number
LT2744515T
LT2744515T LTEPPCT/EP2012/065906T LT12065906T LT2744515T LT 2744515 T LT2744515 T LT 2744515T LT 12065906 T LT12065906 T LT 12065906T LT 2744515 T LT2744515 T LT 2744515T
Authority
LT
Lithuania
Prior art keywords
antibody
combination therapy
nitrogen mustard
mustard
nitrogen
Prior art date
Application number
LTEPPCT/EP2012/065906T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jutta AMERSDORFER
Stefan Steidl
Mark Winderlich
Susanne KROHN
Lisa Rojkjaer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of LT2744515T publication Critical patent/LT2744515T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LTEPPCT/EP2012/065906T 2011-08-16 2012-08-14 Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis LT2744515T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US201261654097P 2012-06-01 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (1)

Publication Number Publication Date
LT2744515T true LT2744515T (lt) 2022-04-25

Family

ID=47714801

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2012/065906T LT2744515T (lt) 2011-08-16 2012-08-14 Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis

Country Status (24)

Country Link
US (3) US20140255427A1 (enExample)
EP (2) EP4062936A1 (enExample)
JP (1) JP6184952B2 (enExample)
KR (3) KR102115203B1 (enExample)
CN (1) CN103732252B (enExample)
AU (1) AU2012296907B2 (enExample)
BR (1) BR112013033919B1 (enExample)
CA (2) CA3137321A1 (enExample)
CY (1) CY1125122T1 (enExample)
DK (1) DK2744515T3 (enExample)
ES (1) ES2909722T3 (enExample)
HR (1) HRP20220228T1 (enExample)
HU (1) HUE058350T2 (enExample)
IL (1) IL230293B (enExample)
LT (1) LT2744515T (enExample)
MX (1) MX354479B (enExample)
PL (1) PL2744515T3 (enExample)
PT (1) PT2744515T (enExample)
RS (1) RS63238B1 (enExample)
RU (1) RU2625222C2 (enExample)
SG (1) SG10201606785UA (enExample)
SI (1) SI2744515T1 (enExample)
SM (1) SMT202200159T1 (enExample)
WO (1) WO2013024097A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157553A4 (en) * 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
JP6916741B2 (ja) 2015-05-26 2021-08-11 モルフォシス・アーゲー 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
AU2016311136B2 (en) * 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
ES2981046T3 (es) * 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
HUE063119T2 (hu) 2017-05-31 2024-01-28 Morphosys Ag Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
US20230357392A1 (en) * 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CA2326389C (en) * 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
IL146005A0 (en) * 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
EP1814544A4 (en) 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) * 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) * 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
EA201170940A1 (ru) * 2009-01-16 2012-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
BR112012003066A2 (pt) * 2009-08-14 2016-11-16 Roche Glycart Ag uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado
WO2011057222A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
HRP20220228T1 (hr) 2022-05-13
KR102115203B1 (ko) 2020-05-28
DK2744515T3 (da) 2022-03-28
EP2744515B1 (en) 2022-02-09
HUE058350T2 (hu) 2022-07-28
SMT202200159T1 (it) 2022-05-12
SI2744515T1 (sl) 2022-05-31
BR112013033919B1 (pt) 2022-11-16
US20140255427A1 (en) 2014-09-11
ES2909722T3 (es) 2022-05-10
KR20190107749A (ko) 2019-09-20
KR20200058583A (ko) 2020-05-27
NZ617770A (en) 2016-01-29
CA2841875A1 (en) 2013-02-21
US20240366756A1 (en) 2024-11-07
RU2014103492A (ru) 2015-09-27
RS63238B1 (sr) 2022-06-30
CA3137321A1 (en) 2013-02-21
PT2744515T (pt) 2022-05-19
IL230293B (en) 2019-01-31
JP2014525926A (ja) 2014-10-02
US20200353077A1 (en) 2020-11-12
MX354479B (es) 2018-03-07
CY1125122T1 (el) 2024-12-13
AU2012296907B2 (en) 2017-01-05
CN103732252A (zh) 2014-04-16
RU2625222C2 (ru) 2017-07-12
BR112013033919A2 (pt) 2017-12-19
MX2013014933A (es) 2014-04-16
JP6184952B2 (ja) 2017-08-23
KR20140064873A (ko) 2014-05-28
EP2744515A1 (en) 2014-06-25
CA2841875C (en) 2021-11-02
EP4062936A1 (en) 2022-09-28
SG10201606785UA (en) 2016-10-28
PL2744515T3 (pl) 2022-05-30
WO2013024097A1 (en) 2013-02-21
CN103732252B (zh) 2017-11-10

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL272831B (en) Meditops and Meditop binding antibodies and their use
IL230293B (en) Combined treatment with anti-19cd antibody and nitrogen mustard
IL259436A (en) Antibodies against 3angptl and their uses
DK2729170T3 (en) Antibody variants and uses thereof
ZA201401843B (en) Antibodies against tl1a and uses thereof
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
ZA201401835B (en) Combination therapy with an anti-cd19 antibody and a purine analog
SI2906252T1 (sl) Pirolobenzodiazepin-anti-HER2 protitelesni konjugati
EP2690427A4 (en) DEVICE FOR REINFORCING OPTICAL ELECTRICAL FIELDS AND MEASURING DEVICE THEREWITH
ZA201306848B (en) Transverse driven-roller belt and convetor
GB201102708D0 (en) Improved containers and assembly thereof